Xinjian Li
- Cancer Research top 0.5%
- Cancer, Hypoxia, and Metabolism 11
- Molecular Biology top 2%
- Metabolism, Diabetes, and Cancer 7
- Epigenetics and DNA Methylation 7
- Immunology top 5%
- Immune cells in cancer 4
- interferon and immune responses 3
- Biochemistry top 5%
- Cell Biology top 5%
-
- Autophagy in Disease and Therapy 8
-
- Cancer-related Molecular Pathways 4
-
- Catalytic C–H Functionalization Methods 3
- Partner nations
- ChinaUnited StatesSouth Korea
In The Last Decade
Xinjian Li
62 papers receiving 4.8k citations
Hit Papers
Peers
Comparison fields: 5 of 125
- Cancer Research 1.9k
- Molecular Biology 3.1k
- Immunology 515
- Biochemistry 173
- Cell Biology 353
Countries citing papers authored by Xinjian Li
This map shows the geographic impact of Xinjian Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xinjian Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xinjian Li more than expected).
Fields of papers citing papers by Xinjian Li
This network shows the impact of papers produced by Xinjian Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xinjian Li. The network helps show where Xinjian Li may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Xinjian Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 3 | |
| 2 | 2024 | 2 | |
| 3 | 2024 | 2 | |
| 4 | 2024 | 3 | |
| 5 | 2022 | 44 | |
| 6 | 2021 | 158 | |
| 7 | 2021 | 36 | |
| 8 | 2020 | 115 | |
| 9 | The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesisbreakdown → | 2020 | 260 |
| 10 | 2019 | 1 | |
| 11 | 2019 | 119 | |
| 12 | 2017 | 67 | |
| 13 | 2017 | 132 | |
| 14 | 2017 | 260 | |
| 15 | 2016 | 139 | |
| 16 | 2016 | 45 | |
| 17 | 2016 | 142 | |
| 18 | 2015 | 164 | |
| 19 | 2013 | 185 | |
| 20 | PKM2 Phosphorylates Histone H3 and Promotes Gene Transcription and Tumorigenesisbreakdown → | 2012 | 672 |
About Xinjian Li
Xinjian Li is a scholar working on Cancer Research, Molecular Biology and Oncology, having authored 66 papers that have together received 4.8k indexed citations. Recurring topics across this work include Cancer, Hypoxia, and Metabolism (11 papers), Autophagy in Disease and Therapy (8 papers), Metabolism, Diabetes, and Cancer (7 papers), Epigenetics and DNA Methylation (7 papers), Cancer-related Molecular Pathways (4 papers), Immune cells in cancer (4 papers), interferon and immune responses (3 papers) and Catalytic C–H Functionalization Methods (3 papers). The work is most often cited by research in Cancer Research (1.9k citations), Molecular Biology (3.1k citations) and Immunology (515 citations). Xinjian Li has collaborated with scholars based in China, United States and South Korea. Frequent co-authors include Zhimin Lu, Yan Xia, Xu Qian, Yanhua Zheng, David H. Hawke, Weiwei Yang, Kenneth Aldape, Tony Hunter, Yuhui Jiang and Ji Liang. Their work appears in journals such as Nature, Cell and Nature Communications.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.